• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

New XARELTO ® (rivaroxaban) Peripheral Artery Disease (PAD) Data from EXPLORER Clinical Research Program to be Unveiled at American Heart Association (AHA) Scientific Sessions 2020
RARITAN, N.J., November 9, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that 10 data presentations will be shared at the virtual American Heart Association (AHA) Scientific Sessions 2020 from November 13-17. Most notably, four new sub-analyses of XARELTO® (rivaroxaban) from the landmark VOYAGER PAD trial, part of the EXPLORER global cardiovascular research program, will be presented, including two live, featured science oral presentations. “We're pleased VOYAGER PAD was selected to be front and center once again at a major medical congress, as there's an urgent need for data in ...
Source: Johnson and Johnson - November 9, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Aortic Valve Replacement in the Moderately Elevated Risk Patient: A Population-Based Analysis of Outcomes
Conclusions This population-based contemporary assessment suggests moderate-risk patients undergoing AVR experience favorable outcomes. Although increasing PROM is important in preoperative evaluation of risk, preexisting pulmonary hypertension and indication for operation are among other factors that should be considered as TAVR expands into this group of patients.
Source: The Annals of Thoracic Surgery - June 17, 2016 Category: Cardiovascular & Thoracic Surgery Source Type: research

Aortic Valve Replacement in the Moderately Elevated Risk Patient: A Population-Based Analysis of Outcomes.
CONCLUSIONS: This population-based contemporary assessment suggests moderate-risk patients undergoing AVR experience favorable outcomes. Although increasing PROM is important in preoperative evaluation of risk, preexisting pulmonary hypertension and indication for operation are among other factors that should be considered as TAVR expands into this group of patients. PMID: 27324524 [PubMed - as supplied by publisher]
Source: The Annals of Thoracic Surgery - June 17, 2016 Category: Cardiovascular & Thoracic Surgery Authors: Patel HJ, Likosky DS, Pruitt AL, Murphy ET, Theurer PF, Prager RL Tags: Ann Thorac Surg Source Type: research

Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement for Severe Aortic Stenosis in Patients With Chronic Kidney Disease Stages 3b to 5
Conclusions CKD stages 3b to 5 increases the risk of mortality after TAVI and SAVR. In this subset of patients, SAVR was associated with somewhat better early and late survival. The risk of acute kidney injury was higher after SAVR. These findings suggest that CKD stages 3b to 5 does not contraindicate SAVR. Strategies to prevent severe acute kidney injury should be implemented with either SAVR or TAVI.
Source: The Annals of Thoracic Surgery - July 19, 2016 Category: Cardiovascular & Thoracic Surgery Source Type: research

Association of Chronic Kidney Disease With In-Hospital Outcomes of Transcatheter Aortic Valve Replacement
Conclusions Patients with CKD or ESRD have worse in-hospital outcomes after TAVR. AKI is associated with higher in-hospital mortality in patients undergoing TAVR and the incidence of AKI has not declined over the years.
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - October 16, 2017 Category: Cardiology Authors: Gupta, T., Goel, K., Kolte, D., Khera, S., Villablanca, P. A., Aronow, W. S., Bortnick, A. E., Slovut, D. P., Taub, C. C., Kizer, J. R., Pyo, R. T., Abbott, J. D., Fonarow, G. C., Rihal, C. S., Garcia, M. J., Bhatt, D. L. Tags: Structural Source Type: research

Comparison of Outcomes of Transcatheter Versus Surgical Aortic Valve Replacement in Patients with Chronic Kidney Disease
There are few data comparing outcomes of transcatheter aortic valve implantation (TAVI) vs. surgical aortic valve replacement (SAVR) in patients with chronic kidney disease (CKD). In this retrospective cohort study using the National Inpatient Sample 2011 – 2014, we included a total of 2820 TAVI and 4054 SAVR procedures, representative of 14,039 TAVI and 19,835 SAVR procedures nationally. Co-primary outcomes were in-hospital mortality, acute kidney injury (AKI), dialysis-requiring AKI, and post-operative stroke.
Source: The American Journal of Cardiology - October 31, 2017 Category: Cardiology Authors: Nilay Kumar, Rohan Khera, Neetika Garg, Justin B. Echouffo-Tcheugui, Anand Venkatraman, Ambarish Pandey, Deepak L. Bhatt Source Type: research

Transcatheter or surgical aortic valve replacement in patients with advanced kidney disease: A propensity score –matched analysis
ConclusionsIn patients with advanced kidney disease, SAVR was associated with higher mortality and higher periprocedural complications, as compared with TAVR. Thus, benefits of TAVR could be extended in patients with advanced kidney disease who cannot undergo surgery.
Source: Clinical Cardiology - October 1, 2017 Category: Cardiology Authors: Rajkumar Doshi, Jay Shah, Vaibhav Patel, Varun Jauhar, Perwaiz Meraj Tags: CLINICAL INVESTIGATIONS Source Type: research

Comparative Surgical Outcomes of Prosthetic and Native Valve Endocarditis
CONCLUSIONS: PVE carried significant perioperative risks, and was an independent risk factor of overall mortality.PMID:34085423 | DOI:10.4070/kcj.2020.0448
Source: Korean Circulation Journal - June 4, 2021 Category: Cardiology Authors: Won Kyung Pyo Ho Jin Kim Joon Bum Kim Sung Ho Jung Suk Jung Choo Cheol Hyun Chung Jae Won Lee Source Type: research

Pages: 1  2